Upper Respiratory Tract Infection Clinical Trial
Official title:
A Two-Treatment, Sequential, Crossover Study of the Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection (Infectious Rhinitis)
Verified date | July 2022 |
Source | ARS Pharmaceuticals, Inc. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This is a Phase 1, single-dose, two-period study that will consist of a combined screening and baseline period and an open-label treatment period. Subjects will be enrolled when they experience an Upper Respiratory Tract Infection with nasal congestion and edema.
Status | Completed |
Enrollment | 15 |
Est. completion date | July 25, 2022 |
Est. primary completion date | March 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 55 Years |
Eligibility | Inclusion Criteria: - Treatment Period 1 only, subject has symptoms of an URTI at time of dosing based on the clinical judgement and the positive infectious cause of URTI to be confirmed by Respiratory Pathogens Panel. - Has body weight more than 55 kg for male and 50 kg for female and body mass index between 18 and 32 kg/m2, inclusive. - Has no declared medical history of hypertension and cardiovascular disease in the last 10 years. - At screening, has stable vital signs in the following ranges (after 5 minutes of rest): - SBP =90 and =140 mmHg - DBP =50 and =90 mmHg - HR =45 and =100 beats per minute (bpm) - Is a nonsmoker within the previous 2 months (calculated from first dosing) and does not use tobacco-containing products. Exclusion Criteria: - Has a stated history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results. - Has current or past history of clinically significant asthma or angioedema. - Has prior nasal fractures, severe nasal injuries or history of nasal disorders that could interfere with nasal spray administration. - Has any clinically significant medical condition or physical exam (PE) finding as deemed inappropriate by the Investigator. - Has abnormal cardiovascular exam at screening including any prior history of myocardial infarction or clinically significant abnormal ECG. - Subject reports they have had significant traumatic injury, major surgery or open biopsy within 30 days prior to study screening. - Subject reports they have donated blood including platelets or plasma only or had an acute loss of blood (>50 mL) during the 30 days before study drug administration or intends to donate blood or blood products within 30 days after the completion of the study. - Has a history (within 12 months before screening) of drug use, or has a positive test for drugs of abuse at screening or upon admittance to the study center, or has a stated history of alcohol abuse. - Has been on an abnormal diet during the four (4) weeks from Day 0. 10. Has participated in a clinical trial within 30 days prior to the first dose of study drug. 11. Has had treatment with any adrenaline or noradrenaline containing products within 7 days of Day 0. 12. Has inadequate or difficult venous access that may jeopardize the quality or timing of the PK samples. |
Country | Name | City | State |
---|---|---|---|
Australia | Anthony McGirr | Brookvale | New South Wales |
Lead Sponsor | Collaborator |
---|---|
ARS Pharmaceuticals, Inc. |
Australia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To evaluate the bioavailability (Cmax) of ARS-1 after intranasal administration | Blood samples will be collected to measure plasma concentrations of adrenaline | Day -1 to Day 30 | |
Primary | To evaluate the bioavailability (AUC0-t) of ARS-1 after intranasal administration | Blood samples will be collected to measure plasma concentrations of adrenaline | Day -1 to Day 30 | |
Primary | To evaluate the bioavailability (tmax) of ARS-1 after intranasal administration | Blood samples will be collected to measure plasma concentrations of adrenaline | Day -1 to Day 30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT06052540 -
Probiotic Supplementation in Children Affected by Upper Respiratory Infections
|
N/A | |
Completed |
NCT04960878 -
The Effect of Synbiotics on the Upper Respiratory Tract Infection
|
N/A | |
Terminated |
NCT00979667 -
A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection
|
Phase 3 | |
Recruiting |
NCT04479657 -
Qingfei Granule for the Treatment of the Pediatric Acute Upper Respiratory Tract Infection With Bacterial Infection
|
Early Phase 1 | |
Completed |
NCT04239521 -
The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
|
||
Recruiting |
NCT06065176 -
The Efficacy of the 2023-2024 Updated COVID-19 Vaccines Against COVID-19 Infection
|
Phase 4 | |
Recruiting |
NCT01985620 -
The Impact of a Short Intervention During RSV Prophylaxis on Influenza Vaccination Rate.
|
N/A | |
Completed |
NCT01875757 -
Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life
|
Phase 3 | |
Recruiting |
NCT00551382 -
Montelukast as Prophylaxis for Upper Respiratory Tract Infections in Children: a Randomised, Double-blind, Placebo-controlled Study
|
Phase 3 | |
Completed |
NCT00393835 -
A Trial Of Azithromycin SR For The Treatment Of Laryngopharyngitis or Tonsillitis or Acute Bacterial Rhinosinusitis
|
Phase 3 | |
Not yet recruiting |
NCT05612893 -
Discover the Immune Signature of Sepsis Caused by Acute Pulmonary Infection: A Cohort Study
|
||
Completed |
NCT06149117 -
Bioequivalence Study of Azithromycin Capsule and Reference Formulation Sumamed * in Healthy Adult Subjects in China
|
Phase 4 | |
Active, not recruiting |
NCT05569330 -
Effect of Aerosol Filtering on Infectious Diseases in Day Care
|
N/A | |
Recruiting |
NCT05374070 -
Antiviral Activity of Oral Probiotics
|
N/A | |
Completed |
NCT00707941 -
Oseltamivir Randomised Controlled Efficacy Trial
|
Phase 3 | |
Completed |
NCT00858494 -
Homeopathic Cold Medicine for Children
|
N/A | |
Completed |
NCT04955327 -
To Compare the Efficacy and Tolerability of A. Paniculata/A. Chilensis in Individuals With URTI
|
Phase 3 | |
Completed |
NCT01735084 -
Using Pneumococcal Vaccines in Combination for Maximum Protection From Ear and Lung Infections in First 3 Years of Life
|
Phase 4 | |
Not yet recruiting |
NCT03461692 -
A Registry Study of 100 Thousand Cases of Pediatric Patients on Reduning Injection(a Chinese Medicine Injection)Used in Hospitals in China
|
N/A | |
Completed |
NCT03011515 -
Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
|